GigaMune
GigaMune is a San Francisco-based biotechnology company specializing in *in vivo* cell therapies for cancer and inherited blood disorders. They aim to overcome manufacturing bottlenecks associated with current cell therapies, such as CAR-T, by developing a method of infusing viral gene delivery vectors directly into patients. The company leverages advanced algorithms, high-throughput genomics, and artificial intelligence to design gene delivery vectors with precise molecular targeting, as well as identify optimal CARs and cell-tropic antibodies. Their pipeline includes treatments for multiple myeloma, acute myeloblastic leukemia (AML), and sickle cell disease. GigaMune's approach also avoids the medical risks associated with lymphodepletion required by other cell therapies.
GigaMune
GigaMune is a San Francisco-based biotechnology company specializing in *in vivo* cell therapies for cancer and inherited blood disorders. They aim to overcome manufacturing bottlenecks associated with current cell therapies, such as CAR-T, by developing a method of infusing viral gene delivery vectors directly into patients. The company leverages advanced algorithms, high-throughput genomics, and artificial intelligence to design gene delivery vectors with precise molecular targeting, as well as identify optimal CARs and cell-tropic antibodies. Their pipeline includes treatments for multiple myeloma, acute myeloblastic leukemia (AML), and sickle cell disease. GigaMune's approach also avoids the medical risks associated with lymphodepletion required by other cell therapies.